Single-country clinical trial results: Are they applicable to other populations?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The rapid acceleration of drug development has exponentially increased the therapeutic options available to patients with cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Edward S. Kim, MD, MBA, FACP, FASCO
Physician-in-Chief, Orange County; Vice Physician-in-Chief, City of Hope National Medical Center
Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. 
FDA approved penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
Edward S. Kim, MD, MBA, FACP, FASCO
Physician-in-Chief, Orange County; Vice Physician-in-Chief, City of Hope National Medical Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login